Harmony Biosciences Holdings, Inc. (HRMY): R&D Expense
$189.59M
Year ended 2025-12-31
$220.87M
Trailing 12 months to 2026-06-30
+38.8%
3-year compound annual growth
+57.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $189.59M | +30.0% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $145.82M | +91.7% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $76.06M | +7.3% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $70.89M | +133.4% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $30.37M | +56.1% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $19.45M | -72.1% | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | $69.59M | n/a | 2022-02-28, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $189.59M | +30.0% |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $51.66M | +15.9% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $607.16M | +20.0% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $915.62M | +1.6% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $388.52M | +64.1% |
| Collegium Pharmaceutical, Inc (COLL) | 2024-12-31 | $0 | n/a |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $254.91M | +3.2% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $53.20M | -24.8% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $117.31M | +43.8% |
Compare HRMY, ANIP, ARWR, IONS side by side · Screen every company in Pharmaceutical Preparations ↗